120 related articles for article (PubMed ID: 22653202)
1. Can next-generation antibodies offset biosimilar competition?
Mullard A
Nat Rev Drug Discov; 2012 Jun; 11(6):426-8. PubMed ID: 22653202
[No Abstract] [Full Text] [Related]
2. Next-generation monoclonals less profitable than trailblazers?
Mitchell P
Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347
[No Abstract] [Full Text] [Related]
3. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
4. Tysabri back on market.
Sheridan C
Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
[No Abstract] [Full Text] [Related]
5. Toward biosimilar monoclonal antibodies.
Schneider CK; Kalinke U
Nat Biotechnol; 2008 Sep; 26(9):985-90. PubMed ID: 18779806
[No Abstract] [Full Text] [Related]
6. Just mad about mAbs.
Jacobs T
Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498
[No Abstract] [Full Text] [Related]
7. The end of the beginning?
Nat Biotechnol; 2006 Apr; 24(4):367. PubMed ID: 16601702
[No Abstract] [Full Text] [Related]
8. Overhauling oversight--European drug legislation.
Tsang L
Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
[TBL] [Abstract][Full Text] [Related]
9. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
10. The pitfalls in the development of biologic therapy.
Maini RN; Feldmann M
Nat Clin Pract Rheumatol; 2007 Jan; 3(1):1. PubMed ID: 17202998
[No Abstract] [Full Text] [Related]
11. Can 'double blockbuster' strengthen Amgen's backbone?
Sheridan C
Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
[No Abstract] [Full Text] [Related]
12. First monoclonal antibody biosimilars: tackling the challenge of substitution.
Bocquet F; Paubel P
J Med Econ; 2016 Jun; 19(6):645-7. PubMed ID: 27080815
[No Abstract] [Full Text] [Related]
13. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany.
Reichert JM
MAbs; 2011; 3(3):223-40. PubMed ID: 21487235
[TBL] [Abstract][Full Text] [Related]
14. Look-alike drugs and unfair competition. An update of Inwood Laboratories v. Ives Laboratories.
Shapiro LJ
Am Pharm; 1985 Oct; NS25(10):49-50. PubMed ID: 4061279
[No Abstract] [Full Text] [Related]
15. IL-1 trap go-ahead.
Ratner M
Nat Biotechnol; 2008 May; 26(5):485. PubMed ID: 18464767
[No Abstract] [Full Text] [Related]
16. Anti-inflammatory inflames Centocor's profits.
Glaser V
Nat Biotechnol; 1998 Oct; 16(10):900. PubMed ID: 9788334
[No Abstract] [Full Text] [Related]
17. Implementation of the biosimilar pathway: economic and policy issues.
Grabowski H; Long G; Mortimer R
Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
[No Abstract] [Full Text] [Related]
18. Non-clinical safety studies on biosimilar recombinant human erythropoietin.
Parnham MJ; Schindler-Horvat J; Kozlović M
Basic Clin Pharmacol Toxicol; 2007 Feb; 100(2):73-83. PubMed ID: 17244255
[TBL] [Abstract][Full Text] [Related]
19. Big Pharma's small wonder.
Fry E
Fortune; 2014 Jun; 169(8):178-84, 186. PubMed ID: 25211849
[No Abstract] [Full Text] [Related]
20. A dose of reality for rational therapies.
Nat Biotechnol; 2005 Mar; 23(3):267. PubMed ID: 15765066
[No Abstract] [Full Text] [Related]
[Next] [New Search]
